
FDA Approves Bevacizumab Biosimilar for Various Cancer Types
The FDA has approved bevacizumab-nwgd (Jobevne; Biocon Biologics), a biosimilar referencing bevacizumab (Avastin; Genentech) for the treatment of several different types of cancers. This approval marks bevacizumab-nwgd as the sixth reference product to …